U.S. drugmaker Perrigo agreed Monday to buy Ireland's Elan for $8.6 billion in a deal that should allow the rapidly growing company to reduce its tax bill and boost its royalty stream.
Health care giant Johnson & Johnson's second-quarter profit more than doubled, thanks to higher sales of medicines and medical devices as it recovers from recalls and manufacturing problems that cut into ...
(AP)—Higher prices for its multiple sclerosis drug Rebif helped German pharmaceutical and high-tech materials company Merck KGaA post a 54 percent rise in first-quarter profit.
(AP)—French drug maker Sanofi said Thursday its net profit was slashed in the first quarter from a year earlier as falling sales and patent losses on key drugs combined to hammer earnings.
Danish pharmaceutical company Lundbeck Wednesday posted a higher than expected quarterly net profit, helped by the expansion of an alliance with Japan's Otsuka and the divestment of a US portfolio of non-core products.
(AP)—Danish pharmaceutical company Novo Nordisk A/S says first-quarter net profit rose 28 percent on strong sales of its diabetic drugs.
German chemical and pharmaceutical company Bayer AG said Thursday that its net profit rose 11.5 percent in the first quarter as new drugs, led by blood thinner Xarelto, boosted sales.
British drugs firm GlaxoSmithKline on Wednesday said its first-quarter net profit tumbled by almost a third, with the group hit by falling sales and a poor economic climate.
(AP)—Swiss pharmaceutical company Novartis AG reported a 6.7 percent increase in profit for the first quarter Wednesday, boosted by new products and emerging markets.
Raising tobacco prices is one of the most effective means of reducing tobacco use, particularly among price-sensitive smokers such as young people and people with low incomes. But when the UK government has been raising cigarette ...
People buy larger amounts of soda when purchasing packs of smaller drinks than when offered single servings of different sized drinks, according to research published April 10 in the open access journal PLOS ONE by Brent ...
Merck KGaA saw its profit more than double in the fourth quarter as the German pharmaceutical company benefited from higher prices for its Rebif multiple sclerosis drug and reaped rewards from its ongoing restructuring.
(AP)—Charges for lawsuits over its birth control pills weighed on Bayer AG's earnings once again during the fourth quarter of 2012.
British drugs firm GlaxoSmithKline on Wednesday unveiled a 13-percent drop in annual net profits and outlined a plan for more restructuring in Europe to deliver greater savings and offset weaker sales across the region.
Merck & Co.'s fourth-quarter profit fell 7 percent because of hits from generic competition and one-time charges, and the company pushed back plans to seek approval of a key experimental osteoporosis drug.